Unlock instant, AI-driven research and patent intelligence for your innovation.

Improved neurturin molecules

A technology of neurotrophic factors and polynucleotides, applied in the direction of growth factors/inducing factors, neuregulins, nervous system diseases, etc., can solve the problems that the regions are not fully conserved and cannot be accurately inferred

Inactive Publication Date: 2012-09-26
NTF THERAPEUTICS
View PDF64 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0016] Although GDNF, ARTN, and NRTN are homologous and contain generally similar structures, neither the N-terminal region of the mature protein nor the region surrounding the theoretical heparin-binding sequence is well conserved
Therefore, precise predictions of the role of these protein domains in NRTN cannot be precisely inferred from studies derived from GDNF or ARTN

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Improved neurturin molecules
  • Improved neurturin molecules
  • Improved neurturin molecules

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0268] Example 1: Molecular Modeling

[0269] Preliminary analysis of the primary sequence of neurotrophic factor reveals a segment of residue (RRLRQRRRLRRER) (SEQ.ID.NO 31) in the heel region of neurotrophic factor, and its consensus sequence for binding to heparin is especially consistent with the sequence "BBXB" or "BBBXXB ", where B is a basic amino acid and X is any residue (Hileman et al. (1998) Bioessays. 20(2):156-67). Although the identification of this sequence is consistent with heparin binding, it should be noted that the findings of this consensus sequence in protein primary structure do not imply that this sequence is necessarily involved in heparin binding. In particular, it has been established that i) proteins lacking these consensus sequences can still bind heparin (Delacoux et al. (2000) J. Biol. Chem. 275(38):29377-82), and ii) contain this motif The protein may not bind heparin.

[0270] Indeed, for all proteins, the ability of consecutive arrays of str...

Embodiment 2

[0276] Example 2: Generation of Neurotrophic Factor Variants

[0277] DNA encoding human neurotrophic factor corresponding to accession number BC137399 was purchased from OpenBiosystems. The mature sequence of neurotrophin (excluding its endogenous signal sequence and pro-sequence) was subcloned into vector pSJP-2 whose vector backbone was based on pAAV-MCS (Stratagene ), which encodes an IgG signal sequence (Fjord-Larsen et al., (2005) "Efficient in vivo protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct (modified neurotrophic factor construct by lentiviral gene transfer Efficient in vivo protection of substantia nigra dopaminergic neurons)." Exp Neurol 195:49-60), followed by the generation of mature neurotrophic factor sequences without the prosequence. E778 was used as template for inverse PCR mutagenesis. Primers for untagged neurturin variant N1 were: F / 5'-ag gcg cgg gcc ctg cgg cgg gag cgggtg cgc-3' (SEQ ID NO: 11...

Embodiment 3

[0279] Example 3: Production and purification of neurotrophic factor variants

[0280] CHO cells were transiently transfected with E436(GFP), V5-tagged wild-type neurturin, or V5-tagged neurturin variants NV1-NV4. Transfection was performed using Turbofect (Fermentas) according to the manufacturer's instructions. After four hours, the medium containing the transfection reagent was replaced with normal medium consisting of DMEM (Sigma), 10% FBS (HyClone), 100 U / ml penicillin (Gibco) and 100 μg / ml streptomycin (Gibco) . After two days, the medium was collected from each plate. To pellet floating cells, the medium was centrifuged (5 minutes, 16,200 xg) before use. Harvested samples were loaded on 15% SDS-PAGE and analyzed by Western blotting with V5-antibody (Invitrogen). All variants were successfully expressed and secreted into the medium, and showed correct predicted molecular weights on SDS-PAGE (data not shown).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Molecular weightaaaaaaaaaa
Login to View More

Abstract

Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease is also disclosed.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of US Provisional Patent Application No. 61 / 256352, filed October 30, 2009, which is incorporated by reference in its entirety. Background technique [0003] The present invention relates to the development and use of enhanced neurturin polypeptides possessing reduced binding affinity for heparin and heparan sulfate, yet retaining neurotrophic activity; nucleic acids encoding said neurturin variants and vectors, and expression of enhanced neurturin Host cells for factor polypeptides. In addition, the present invention also includes the use of the enhanced neurotrophic factor polypeptide, nucleic acid and host cell in treating diseases. [0004] Glial cell line-derived neurotrophic factor (GDNF) family ligands (GFLs), distant members of the TGF-β superfamily, are potent neurotrophic factors in vitro and are important for the development of diverse neuronal populations in vivo ( Airaks...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K14/47A61K38/17A61P25/00
CPCC07K14/4756A61K38/00C07K14/475A61P1/00A61P15/10A61P17/14A61P21/02A61P25/00A61P25/02A61P25/04A61P25/14A61P25/16A61P25/28A61P27/02A61P27/16A61P31/00A61P35/00A61P43/00A61P9/10A61P3/10
Inventor 皮亚·鲁内贝里-鲁斯马克西姆·别斯帕洛夫理查德·佩恩马特·萨玛
Owner NTF THERAPEUTICS